SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock approaches its all-time high, driven by optimism around robotaxi advancements and analyst upgrades. Community discussions highlight the potential for a continued rally, while some traders express caution, citing valuation concerns and the possibility of a pullback. Bullish sentiment prevails, with many anticipating a further price increase.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential cannabis rescheduling, with community members closely watching for news and a possible executive order. The discussions revolve around the potential impact on Canadian companies, short squeezes, and the broader implications for the cannabis sector. Bullish sentiment seems to be building, with some anticipating significant gains if the rescheduling occurs.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its recent de-SPAC status and resulting momentum, with traders actively discussing its potential for a short squeeze given the high cost to borrow and low float. The community is focused on removing stop losses and setting high limit orders, anticipating a rally similar to SMX. Bullish sentiment is high as traders encourage each other to hold strong and combat perceived short attacks.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial is trending as traders discuss the potential for a short squeeze, fueled by high short interest and recent positive signals like a swing to profitability in Q2. Community members are actively debating the impact of potential filings and compliance with Nasdaq regulations, with some expressing optimism about the stock's turnaround potential and others remaining skeptical. The stock's low P/E ratio and hard-to-borrow status are also contributing to the bullish sentiment.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its strong community and compare it to Bitcoin, emphasizing a culture-focused approach. Discussions revolve around its roots on the Solana blockchain and the potential for growth within the cannabis industry. The community uses terms like "WAGMI" and encourages others to join their X community.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as the cannabis sector anticipates potential rescheduling, driven by speculation around an upcoming announcement. Community discussions revolve around the potential impact of rescheduling on US cannabis companies, particularly regarding tax benefits and institutional investment. The ETF's price action reflects optimism, with many expecting significant gains if the rescheduling occurs.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Despite strong fundamentals and expansion news, Luckin Coffee is trending down, frustrating investors. The community is debating whether the recent price action is due to manipulation, large shareholders selling off, or broader market concerns. Some are hopeful for a bounce or relisting catalyst, while others express doubts about management and the company's communication.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as investors debate its future amid a broader pullback in the AI sector, with some citing delayed data center construction and insider selling as causes for concern. Bullish investors point to the company's strong backlog and potential government support, viewing the dip as a buying opportunity. Community members are actively discussing potential support levels and the impact of market volatility on the stock.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending due to strong earnings and raised outlook, with analysts increasing price targets. The community is discussing its potential for continued growth in the AI infrastructure space and debating whether it's a good buy right now. Some traders are also pointing to potential short squeezes and technical indicators suggesting a buying opportunity.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amidst mixed sentiment, with community members debating the stock's future and short selling opportunities. Some express concerns over the company's financial performance and leadership, while others highlight positive aspects like the quality of Lucid's vehicles and potential for a short squeeze. Discussions also include comparisons to Chinese EV manufacturers and speculation about potential partnerships or acquisitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 12-Month High - Here's Why...

Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR

Two Seas Capital LP raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 43.6% in the second quarter, according to the company in its most recent Form 13F...

Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 1-Year High - Should You Buy...

Esperion Therapeutics (NASDAQ:ESPR) Trading 6% Higher - Here's What Happened

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 6% - What's Next...

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...

<ul class="summary-bullets"><li>Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.</li><li>Q3 revenue rose sharply as U.S. product sales and collaboration income continued to strengthen.</li><li>The recent Japan launch and milestones from partner Otsuka added to investor optimism about Esperion’s global expansion.</li></ul>Esperion Therapeutics shares climbed to their highest levels in nearly a year on Tuesday after a bullish initiation from Piper Sandler and fresh progress on the company’s international launch plans helped lift investor sentiment.The stock closed 16.4% higher at $3.69 on Tuesday and edged up another 0.3% in after-hours trading, also logging its best session in almost four months.&nbsp;<h2 class="st-heading-2">Piper Sandler Calls Esperion A Strong Risk-Reward Play</h2>Piper Sandler initiated coverage with an ‘Overweight’ rating and projected a potential 144% upside, describing Esperion as a strong risk-reward play supported by accelerating demand for its cholesterol-lowering drug franchise. The firm highlighted the strength of the company’s bempedoic acid–based therapies, Nexletol and Nexlizet, and said it expects continued rapid volume and sales expansion as physicians shift toward non-statin low-density lipoprotein (LDL)-lowering options, according to a report by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/analyst-ratings/piper-sandler-initiates-esperion-therapeutics-stock-with-overweight-rating-93CH-5124964">Investing</a>.The brokerage pointed to several drivers of long-term growth, including a wide label that covers primary prevention, evolving clinical guidelines that increasingly support the drug class, and broad payer access. A cardiologist-focused survey conducted by the firm reinforced confidence in the therapies’ adoption trajectory.Piper Sandler said it expects Esperion’s products to reach over $650 million in peak U.S. sales, with additional contributions from ex-U.S. royalties, and noted that recent agreements with generic filers provide visibility into exclusivity extending to 2040.Piper Sandler added that Esperion’s risk-reward profile is attractive, noting the stock trades at an enterprise value of roughly 10x estimated 2026 EBITDA, with high visibility into a long-term EBITDA compound annual growth rate above 30% from 2026 through 2031. This long-term view remains intact even as the company reported an EBITDA loss of $29.27 million over the last twelve months.<h2 class="st-heading-2">Esperion Posts Strong Q3 Growth</h2>Esperion reported third-quarter (Q3) total revenue of $87.3 million, an increase of 69% year-on-year, with U.S. net product revenue rising 31% year-on-year to $40.7 million. Collaboration revenue strengthened as well, supported by higher royalty sales and product supply to partners. The company reported an EBITDA loss of $29.27 million, net loss of $31.3 million, and ended the quarter with $92.4 million in cash and cash equivalents. U.S. commercial coverage expanded to more than 90% of commercial lives and over 80% of Medicare beneficiaries, and total prescription volume increased during the period.<h2 class="st-heading-2">Japan Launch Builds Global Momentum</h2>Esperion’s upward momentum comes shortly after a major international milestone. Last week, the company said that its partner Otsuka Pharmaceutical received National Health Insurance Price Listing in Japan and launched Nexletol for hypercholesterolemia and familial hypercholesterolemia. Japan represents the third largest global market for cardiovascular prevention, marking a significant expansion opportunity for Esperion’s cholesterol franchise.Under the agreement, Esperion will receive a $90 million payment tied to Otsuka’s recent regulatory and pricing achievements. The company is also eligible for additional sales milestone payments and tiered royalties of 15% to 30% on net sales in Japan.<h2 class="st-heading-2">Stocktwits Traders Signal Long-Term Confidence</h2>On Stocktwits, retail sentiment for Esperion was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/espr_stock_png_0574a99904.webp" alt="espr stock.png" width="972" height="146"><figcaption>ESPR sentiment and message volume as of November 25 | Source: Stocktwits</figcaption></figure>One user said they did not see a buyout happening soon, noting that Esperion already has a growing commercial drug, additional pipeline assets and a path toward profitability.<stembedurl>https://stocktwits.com/Petey3163/message/637466961</stembedurl>Another user said they expected to remain invested for 18 to 24 months, describing cardiovascular opportunities as early and ESP-2001 as still upcoming, and added that they had built a large position and planned to hold.<stembedurl>https://stocktwits.com/Lskynrd1/message/637466633</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion Therapeutics’ stock</a> has risen 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug 

Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.

Equity

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 4.1% - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 4.1% - Still a Buy...

Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing...

HC Wainwright Has Positive Outlook for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday...

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ESPR News

ESPREsperion Therapeutics Inc.